<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531332</url>
  </required_header>
  <id_info>
    <org_study_id>REC-H-PhBSU-20004</org_study_id>
    <nct_id>NCT04531332</nct_id>
  </id_info>
  <brief_title>Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia</brief_title>
  <official_title>Efficacy and Safety of Continuous Infusion of Linezolid Compared With Intermittent Dosing in Critically Ill Pneumonic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>October 6 University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>October 6 University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's goal in this study is to determine the clinical efficacy and safety of&#xD;
      continuous infusion in comparison with standard intermittent infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized controlled clinical trial on critically ill Pneumonic patients,&#xD;
      included two groups, over one year period. The first group will be administered intravenous&#xD;
      (IV) linezolid 600mg twice daily. The second group will be prescribed linezolid (IV) 600 mg&#xD;
      loading dose followed by 1200 mg by continuous infusion. Both groups will be co-administered&#xD;
      intravenous (IV) Meropenem 1g every 8 hours empirically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of cured patients in the linezolid continuous infusion group versus the proportion of cured patients in the intermittent group</measure>
    <time_frame>through study completion, over one year</time_frame>
    <description>The primary efficacy endpoint will be evaluated as clinical cure on day 7 of Linezolid initiation.&#xD;
Clinical cure defined by normalized body temperature, TLC less than 10,000/mL, absence of purulent secretions, and improvement of radiological findings (x-ray), in addition to Pao2/Fio2 greater than 250 in patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of occurrence of anemia and thrombocytopenia</measure>
    <time_frame>through study completion, over one year</time_frame>
    <description>The patients' hematological parameters (hemoglobin (Hb), hematocrit (Hct), and platelets (PLTs) counts) will be compared every 2 days during linezolid treatment between two groups.&#xD;
Anemia is defined as decrease in hemoglobin level &lt;10 g/dl and Thrombocytopenia is defined as decrese in platelets count &lt;100 × 103/mm3</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">169</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be received linezolid 600 mg intravenous Loading dose over 30 to 60 minutes followed by 1200 mg/ day by Continuous infusion (50 mg /hr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be received Linezolid 600 mg intravenous twice daily over 30 to 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous infusion Linezolid</intervention_name>
    <description>Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )</description>
    <arm_group_label>Continuous infusion</arm_group_label>
    <other_name>intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intermittent dosing linezolid</intervention_name>
    <description>Linezolid 600 mg intravenous twice daily</description>
    <arm_group_label>Intermittent dosing</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to ICUs diagnosed as HAP or VAP&#xD;
&#xD;
          -  Chest X-ray/ computed tomography showing new or progressive infiltrate.&#xD;
&#xD;
          -  New onset of purulent sputum or change in sputum character.&#xD;
&#xD;
          -  Body temperature greater than 38 ℃ or less than 35.5℃.&#xD;
&#xD;
          -  White blood cell counts greater than 10000 /mm3 or less than 4000 /mm3.&#xD;
&#xD;
          -  Significant quantitative pathogen cultures from respiratory secretions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years, Pregnancy, Lactation&#xD;
&#xD;
          -  Previous known allergic reaction to linezolid&#xD;
&#xD;
          -  Creatinine Clearance (CrCl) &lt;10 mL/min, calculated according to the Cockcroft-Gault&#xD;
             formula&#xD;
&#xD;
          -  Thrombocytopenia (platelet count less than 80,000/mm3)&#xD;
&#xD;
          -  Severe hepatic failure (Child-Pugh C)&#xD;
&#xD;
          -  Concomitant treatment with other drugs that can potentially interfere with Linezolid&#xD;
             (i.e., macrolides, serotonin modulators, omeprazole)&#xD;
&#xD;
          -  Acute DIC score &gt; 4 points or hematological disorder&#xD;
&#xD;
          -  Concurrent drug-associated Thrombocytopenia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Adult, Older Adult</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Essam, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>October 6 University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed E Abou warda, BSc</last_name>
    <phone>00201007647696</phone>
    <email>ahmed.essam@o6u.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rania M Sarhan, PhD</last_name>
    <phone>0021008789509</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beni-suef University</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed E Abou Warda, BSc</last_name>
      <phone>00201007647696</phone>
      <email>ahmed.essam@o6u.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Rania M Soliman, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayman N Moharram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heba Farouk, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>October 6 University</investigator_affiliation>
    <investigator_full_name>Ahmed Essam</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>linezolid continuous infusion</keyword>
  <keyword>pneumonia</keyword>
  <keyword>critically ill patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

